Axitinib (AG 013736): Potent VEGFR Inhibitor for Cancer Rese
2026-05-05
Axitinib (AG 013736) is a highly selective, orally bioavailable inhibitor of VEGF receptor tyrosine kinases, extensively used in angiogenesis inhibition assays and tumor growth modulation studies. Its sub-nanomolar potency and robust selectivity profile make it a gold-standard tool in cancer biology research.
BMS-345541: Applied Workflows for IKK-1/IKK-2 Inhibitor Rese
2026-05-04
BMS-345541 (free base) from APExBIO empowers precise dissection of the NF-κB pathway in both inflammation and cancer models. This article delivers actionable workflow strategies, protocol optimization, and troubleshooting insights—bridging cutting-edge literature with bench-ready applications.
Naftifine HCl: Optimizing Allylamine Antifungal Assays in Re
2026-05-04
Naftifine HCl stands out as a high-purity allylamine antifungal agent, enabling precise mechanistic studies of sterol biosynthesis and membrane disruption in fungal pathogens. This guide translates cutting-edge research and product-specific workflows into actionable protocols and troubleshooting strategies for topical antifungal and cell signaling research.
Synergistic Antibacterial Effects of Copper and Hexetidine I
2026-05-03
This article reviews the pivotal 1988 study demonstrating pronounced synergistic antibacterial effects when copper and hexetidine are combined against Streptococcus sobrinus and S. sanguis. The findings provide mechanistic insights and quantitative evidence for improved inhibition of oral streptococci, informing assay design for antibacterial agent evaluation.
Phosbind Acrylamide: Precision Phosphate-Binding in SDS-PAGE
2026-05-02
Phos binding reagent (Phosbind) acrylamide enables antibody-free, phosphate-dependent separation of phosphorylated proteins by SDS-PAGE. This phosphate-binding reagent offers robust detection of phosphorylation states, especially within the 30–130 kDa range, streamlining protein phosphorylation analysis in research workflows.
Cy5 Hydrazide for Precise Carbonyl Labeling in Nanoparticle
2026-05-02
Cy5 hydrazide (non-sulfonated) enables rapid, selective labeling of carbonyl groups in proteins, glycoproteins, and nanoparticles—critical for oxidative stress detection and advanced nanotechnology workflows. Optimized protocols maximize sensitivity and reproducibility, offering a robust alternative to Alexa Fluor 647 with clear troubleshooting strategies.
SAR131675: Applied VEGFR-3 Inhibitor Workflows for Tumor and
2026-05-01
SAR131675, a selective ATP-competitive VEGFR-3 inhibitor, empowers researchers to dissect lymphangiogenesis and angiogenesis in preclinical models with unmatched specificity. This article delivers actionable workflows, troubleshooting tips, and strategic insights to maximize the compound’s impact in anti-lymphangiogenic, anti-angiogenic, and tumor growth inhibition studies.
Saracatinib (AZD0530): Integrating Src Inhibition in Cancer
2026-04-30
Explore Saracatinib (AZD0530) as a dual Src/Abl kinase inhibitor for advanced cancer biology research. This article uniquely emphasizes protocol precision, translational assay design, and cross-talk with synaptic signaling pathways.
Saquinavir in Translational Research: Mechanistic Insights &
2026-04-30
Explore the evolving role of Saquinavir, a leading HIV protease inhibitor, in translational research. This article bridges mechanistic understanding and advanced permeability modeling, offering actionable strategies for antiretroviral and cancer research. Drawing on recent mass spectrometry-based biomimetic chromatography findings, it provides protocol parameters, workflow integration, and a forward-looking perspective—differentiating itself from standard product content through evidence-backed, cross-domain insight.
Enhanced Lysosomal Exocytosis Drives Cartilage Pathology in
2026-04-29
This study establishes that increased lysosomal exocytosis and altered growth factor signaling are central to cartilage pathology in a zebrafish model of mucopolysaccharidosis type IVA (MPS IVA). The findings highlight new mechanisms of skeletal disease pathogenesis beyond substrate accumulation and offer a refined framework for investigating lysosome-mediated signaling disruptions.
Escitalopram for Antidepressant Research: Protocols & Innova
2026-04-29
Escitalopram (Lexapro) stands out as a gold standard SSRI for modeling serotonergic signaling and antidepressant mechanisms, offering unmatched selectivity in preclinical and translational workflows. Discover how APExBIO’s high-purity Escitalopram empowers advanced depression and anxiety research with practical protocol enhancements and troubleshooting strategies.
QNZ (EVP4593): Potent NF-κB Inhibition for Neuroinflammation
2026-04-28
QNZ (EVP4593) is a nanomolar quinazoline derivative that inhibits the NF-κB signaling pathway and demonstrates efficacy in anti-inflammatory and neurodegenerative disease models. Its robust mechanism and solubility profile make it a key tool for research in inflammation and Huntington’s disease.
Cy3 Goat Anti-Mouse IgG (H+L): Benchmarks for Mouse IgG Dete
2026-04-28
The Cy3 Goat Anti-Mouse IgG (H+L) Antibody is a validated fluorescent secondary antibody for sensitive detection of mouse IgG in immunofluorescence, flow cytometry, and western blotting. APExBIO’s K1207 reagent offers robust signal amplification and proven specificity, with defined storage and usage parameters. This article details its mechanism, evidence, and optimal integration into research workflows.
Canagliflozin: SGLT2 Inhibitor Workflows for Mitochondrial R
2026-04-27
Canagliflozin, a selective SGLT2 inhibitor, advances diabetes and kidney disease research by enabling targeted modulation of renal glucose handling and mitochondrial function. This article details protocol strategies, troubleshooting, and evidence-based enhancements for leveraging Canagliflozin in in vitro and in vivo metabolic disease models.
Cinoxacin: Quinolone Antibiotic Workflows for Gram-Negative
2026-04-27
Cinoxacin delivers reliable, quantifiable performance in research on Gram-negative pathogens, especially for urinary tract infection and antibiotic resistance models. This guide translates clinical-grade evidence into stepwise experimental workflows and troubleshooting strategies, empowering scientists to achieve reproducible results with APExBIO's Cinoxacin.
462 records 20/31 page Previous Next First page 上5页 1617181920 下5页 Last page